Influenza News and Research

Latest Influenza News and Research

Study: Chemotherapy can improve survival rate in older adolescents with leukemia

Research led by St. Jude Children-s Research Hospital investigators will likely impact how acute lymphoblastic leukemia is treated in young adults and shows older adolescent age does not dictate worse outcomes against the most common childhood cancer.

21 Dec 2010

Exosomes derived from lymphoma, colorectal cancer patients circulated through Aethlon's Hemopurifier

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it has demonstrated the ability to capture immunosuppressive exosomes derived from individuals with lymphoma and colorectal cancer.

20 Dec 2010

Germany has not yet achieved influenza vaccination rates set by WHO

The World Health Organization set a target for the influenza vaccination rate for 2006 of more than 50% of the elderly population and an increase to more than 75% by 2010. These rates have thus far not been achieved in the old German states. In the current issue of Deutsches Ärzteblatt International (Dtsch Arztebl Int 2010; 107[48]: 845-50) the working group around Annicka M. Reuss presents rates from flu seasons past.

17 Dec 2010

NIAID renews funding of PRIME to develop mathematical models to study influenza infection

Mount Sinai School of Medicine today announced that the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has renewed funding of the Program for Research on Immune Modeling and Experimentation. This program seeks to develop easy-to-use, predictive mathematical models to better understand patterns of infection among individuals affected by the H1N1 and 1918 influenza viruses and other related viruses.

17 Dec 2010

First comprehensive guide to hospital emergency preparedness exercise development

With the publication of the nation's first comprehensive, federally funded guide to hospital emergency preparedness exercise development, Dr. Nathaniel Hupert at Weill Cornell Medical College and his collaborators have provided a new toolset for strengthening hospitals' ability to protect communities nationwide against public health disasters, such as creating care centers during an influenza pandemic or treating casualties in the wake of a bioterrorism attack.

17 Dec 2010

Adeona expands and enhances zinc-based product candidate portfolio

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that it has acquired access to clinical data supporting a zinc-based therapy for the prevention of infections in the elderly. This acquisition expands and enhances Adeona's zinc-based product candidate portfolio that already includes its proprietary zinc-based tablets for use in the dietary management of mild to moderate Alzheimer's disease and mild cognitive impairment patients, and age-related macular degeneration.

16 Dec 2010

Study confirms Carrageenan as effective antiviral against H1N1 influenza strain

Carrageenan, is a polymer derived from red seaweed which helps to create a protective physical barrier in the nasal cavity and has proven to be an effective antiviral in the treatment of the common cold.

16 Dec 2010

Flu vaccination during pregnancy prevents infant hospitalization

A three-year study by Yale School of Medicine researchers has found that vaccinating pregnant women against influenza is over 90 percent effective in preventing their infants from being hospitalized with influenza in the first six months of life.

15 Dec 2010

DARPA awards Pulmatrix $5.7 million grant to advance iCALM therapies

Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases, today announced that it has been awarded a grant for $5.7 million from the Defense Advanced Research Projects Agency (DARPA), a component of the Department of Defense (DOD), focused on identifying and advancing novel technologies to support defense of our nation's soldiers and civilian population.

14 Dec 2010

New theory explains spread of infectious diseases

New research using human-networking theory may give a clearer picture of just how, exactly, infectious diseases such as the common cold, influenza, whooping cough and SARS can spread through a closed group of people, and even through populations at large.

14 Dec 2010

Clinical trail shows 2009 H1N1 influenza vaccine safe and effective in asthma patients

Results from a government-sponsored clinical trial of inactivated 2009 H1N1 influenza vaccine in people with asthma indicate that a single dose of vaccine was safe and induced a strong immune response predictive of protection.

14 Dec 2010

Mouse study shows flu virus infection may protect against asthma

In a paper that suggests a new strategy to prevent asthma, scientists at Children's Hospital Boston and their colleagues report that the influenza virus infection in young mice protected the mice as adults against the development of allergic asthma.

14 Dec 2010

Intercell to stop further development of Travelers' Diarrhea Vaccine Patch

Intercell AG announced today preliminary clinical results on its investigational Travelers' Diarrhea (TD) Vaccine Patch program and the decision not to pursue further the development of this vaccine candidate. The decision was made following the receipt of results of its randomized and placebo-controlled Phase III study (ELT301) with 2036 travelers from Europe to Mexico and Guatemala as well as the pilot efficacy Phase II trial (ELT209) with 723 travelers from Europe to India.

13 Dec 2010

Vical's Vaxfectin adjuvant boosts immune response of DNA-based vaccines against cancer

Vical Incorporated announced today that the company's Vaxfectin® adjuvant has significantly boosted the immune response of DNA-based vaccines against a range of pathogens and cancer in preclinical models from rodents to non-human primates. Vaxfectin® has demonstrated similar effects with protein- and peptide-based vaccines in preclinical models.

13 Dec 2010

New groundbreaking research advances understanding of HIV

It is estimated that 38 million people worldwide are currently infected with HIV and that 4.1 million more are added each year. For scientists to design treatment therapies that are effective over the long-term it is essential to learn more about how the virus mutates and develops resistance to medications.

13 Dec 2010

Researchers develop statistical model to predict severity of seasonal influenza

Researchers have developed a statistical model for projecting how many people will get sick from seasonal influenza based on analyses of flu viruses circulating that season. The research, conducted by scientists at the National Institutes of Health, appears today in the open-access publication PLoS Currents: Influenza.

9 Dec 2010

Lung transplant saves economist from near-lethal bout of swine flu

According to the critical care experts at The Johns Hopkins Hospital who treated him, Allen Bagents, 24, of Arlington, Va., is the least likely person anyone ever expects to get sick, let alone suffer a six-week, potentially fatal bout with the swine flu, better known as H1N1 influenza.

8 Dec 2010

FDLI to launch Food and Drug Policy Forum publication in 2011

In 2011, the Food and Drug Law Institute will launch a new publication — FDLI"s Food and Drug Policy Forum. "The Policy Forum is designed to provide a new electronic marketplace for the exchange of ideas among food and drug law, regulation, and policy professionals," notes Susan C. Winckler, President and CEO of FDLI.

8 Dec 2010

SEEK reports Phase I safety trail for investigational flu vaccine

SEEK, a leading UK privately-owned drug-discovery group, today presented data on the successful conclusion of a Phase I safety and tolerability study for its investigational Universal Influenza Vaccine, FLU-v, at the World Influenza Congress in Amsterdam (7-9 December).

8 Dec 2010

Johnson & Johnson commences recommended cash offer for Crucell

Johnson & Johnson and Crucell N.V. today announced that Johnson & Johnson, through its newly formed indirect wholly owned subsidiary, JJC Acquisition Company B.V. (the Offeror), is making a recommended cash offer for all of the issued and outstanding ordinary shares (Ordinary Shares) in the capital of Crucell N.V. (Crucell), including all Ordinary Shares represented by American depositary shares (ADSs), each ADS representing one Ordinary Share at an offer price of EUR 24.75 per Share (the Offer).

8 Dec 2010